Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $113.7 million.

  • Protagonist Therapeutics' Cash & Equivalents fell 1327.63% to $113.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.7 million, marking a year-over-year decrease of 1327.63%. This contributed to the annual value of $97.2 million for FY2024, which is 4791.92% down from last year.
  • As of Q3 2025, Protagonist Therapeutics' Cash & Equivalents stood at $113.7 million, which was down 1327.63% from $168.5 million recorded in Q2 2025.
  • Protagonist Therapeutics' Cash & Equivalents' 5-year high stood at $355.6 million during Q2 2024, with a 5-year trough of $83.0 million in Q1 2021.
  • For the 5-year period, Protagonist Therapeutics' Cash & Equivalents averaged around $156.6 million, with its median value being $131.1 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 9576.5% in 2023, then crashed by 5260.89% in 2025.
  • Over the past 5 years, Protagonist Therapeutics' Cash & Equivalents (Quarter) stood at $123.7 million in 2021, then grew by 1.68% to $125.7 million in 2022, then skyrocketed by 48.5% to $186.7 million in 2023, then tumbled by 47.92% to $97.2 million in 2024, then grew by 16.93% to $113.7 million in 2025.
  • Its last three reported values are $113.7 million in Q3 2025, $168.5 million for Q2 2025, and $139.7 million during Q1 2025.